Pleiotropic effects of glitazones: A double edge sword?

Frontiers in Pharmacology

Volumn MAR, Issue , 2011, Pages

  Salomone, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Glitazones; Pioglitazone; Rosiglitazone; Troglitazone; Vascular tone

Indexed keywords

ALEGLITAZAR; BALAGLITAZONE; CIGLITAZONE; CYCLIN D1; FARGLITAZAR; GLITAZONE DERIVATIVE; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; AUTISM; BLOOD VESSEL TONE; BONE MASS; BREAST CARCINOMA; DRUG SAFETY; DRUG STRUCTURE; FRACTURE; GENE EXPRESSION; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIVER FAILURE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OSSIFICATION; OVARY POLYCYSTIC DISEASE; PSORIASIS; SIDE EFFECT; TOXIC HEPATITIS; VASOCONSTRICTION; WATER RETENTION;

EID: 84861138368     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00014     Document Type: Article

References (55)

1. Albers, H. M., van Meeteren, L. A., Egan, D. A., van Tilburg, E. W., Moolenaar, W. H., and Ovaa, H. (2010). Discovery and optimization of boronic acid based inhibitors of autotaxin. J. Med. Chem. 53, 4958-4967.
2. Alloatti, G., Montrucchio, G., Lembo, G., and Hirsch, E. (2004). Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease. Biochem. Soc. Trans. 32, 383-386.
3. Baranova, A. (2008). PPAR ligands as potential modifiers of breast carcinoma outcomes. PPAR Res. 2008, 230893.
4. Boden, G., Homko, C., Mozzoli, M., Showe, L. C., Nichols, C., and Cheung, P. (2005). Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54, 880-885.
5. Bodmer, M., Meier, C., Kraenzlin, M. E., and Meier, C. R. (2009). Risk of fractures with glitazones: a critical review of the evidence to date. Drug. Saf. 32, 539-547.
6. Boris, M., Kaiser, C. C., Goldblatt, A., Elice, M. W., Edelson, S. M., Adams, J. B., and Feinstein, D. L. (2007). Effect of pioglitazone treatment on behavioral symptoms in autistic children. J. Neuroinflammation 4, 3.
7. Chen, L., Yang, B., McNulty, J. A., Clifton, L. G., Binz, J. G., Grimes, A. M., Strum, J. C., Harrington, W. W., Chen, Z., Balon, T. W., Stimpson, S. A., and Brown, K. K. (2005). GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther. 312, 718-725.
8. Colin, C., Salamone, S., Grillier-Vuissoz, I., Boisbrun, M., Kuntz, S., Lecomte, J., Chapleur, Y., and Flament, S. (2010). New troglitazone derivatives devoid of PPARgamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res. Treat. 124, 101-110.
9. De Vos, P., Lefebvre, A. M., Miller, S. G., Guerre-Millo, M., Wong, K., Saladin, R., Hamann, L. G., Staels, B., Briggs, M. R., and Auwerx, J. (1996). Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J. Clin. Invest. 98, 1004-1009.
10. Ellis, C. N., Varani, J., Fisher, G. J., Zeigler, M. E., Pershadsingh, H. A., Benson, S. C., Chi, Y., and Kurtz, T. W. (2000). Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch. Dermatol. 136, 609-616.
11. Francis, G. A., Fayard, E., Picard, F., and Auwerx, J. (2003). Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65, 261-311.
12. Fujita, T., Sugiyama, Y., Taketomi, S., Sohda, T., Kawamatsu, Y., Iwatsuka, H., and Suzuoki, Z. (1983). Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32, 804-810.
13. Gelman, L., Feige, J. N., and Desvergne, B. (2007). Molecular basis of selective PPARgamma modulation for the treatment of type 2 diabetes. Biochim. Biophys. Acta 1771, 1094-1107.
14. Geronikaki, A., Eleftheriou, P., Vicini, P., Alam, I., Dixit, A., and Saxena, A. K. (2008). 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. J. Med. Chem. 51, 5221-5228.
15. Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., Garcia-Garcia, H. M., van Es, G. A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., Fitzgerald, P. J., and Nesto, R. W. (2010). Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 121, 1176-1187.
16. Goldberg, R. B. (2006). Impact of thiazolidenediones on serum lipoprotein levels. Curr. Atheroscler. Rep. 8, 397-404.
17. Guh, J. H., Chang, W. L., Yang, J., Lee, S. L., Wei, S., Wang, D., Kulp, S. K., and Chen, C. S. (2010). Development of novel adenosine monophosphate-activated protein kinase activators. J. Med. Chem. 53, 2552-2561.
18. Guo, L., Zhang, L., Sun, Y., Muskhelishvili, L., Blann, E., Dial, S., Shi, L., Schroth, G., and Dragan, Y. P. (2006). Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol. Divers. 10, 349-360.
19. Han, S., Wada, R. K., and Sidell, N. (2001). Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res. 61, 3998-4002.
20. He, K., Woolf, T. F., Kindt, E. K., Fielder, A. E., and Talaat, R. E. (2001). Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. Biochem. Pharmacol. 62, 191-198.
21. Huang, J. W., Shiau, C. W., Yang, J., Wang, D. S., Chiu, H. C., Chen, C. Y., and Chen, C. S. (2006). Development of small-molecule cyclin D1-ablative agents. J. Med. Chem. 49, 4684-4689.
22. Jiang, C., Ting, A. T., and Seed, B. (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
23. Katsiki, N., Georgiadou, E., and Hatzitolios, A. I. (2009). The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Drugs 69, 1417-1431.
24. Kaul, S., Bolger, A. F., Herrington, D., Giugliano, R. P., and Eckel, R. H. (2010). Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 121, 1868-1877.
25. Kletzien, R. F., Clarke, S. D., and Ulrich, R. G. (1992). Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41, 393-398.
26. Lee, Y. H., Chung, M. C., Lin, Q., and Boelsterli, U. A. (2008). Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. Toxicol. Appl. Pharmacol. 231, 43-51.
27. Liu, X., Xie, H., Luo, C., Tong, L., Wang, Y., Peng, T., Ding, J., Jiang, H., and Li, H. (2010). Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. J. Med. Chem. 53, 2661-2665.
28. Loi, C. M., Randinitis, E. J., Vassos, A. B., Kazierad, D. J., Koup, J. R., and Sedman, A. J. (1997). Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J. Clin. Pharmacol. 37, 1114-1120.
29. Luo, Y., Ma, L., Zheng, H., Chen, L., Li, R., He, C., Yang, S., Ye, X., Chen, Z., Li, Z., Gao, Y., Han, J., He, G., Yang, L., and Wei, Y. (2010). Discovery of (Z)-5-(4-methoxybenzylidene) thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. J. Med. Chem. 53, 273-281.
30. Marra, F., Efsen, E., Romanelli, R. G., Caligiuri, A., Pastacaldi, S., Batignani, G., Bonacchi, A., Caporale, R., Laffi, G., Pinzani, M., and Gentilini, P. (2000). Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119, 466-478.
31. Marx, N., Kehrle, B., Kohlhammer, K., Grub, M., Koenig, W., Hombach, V., Libby, P., and Plutzky, J. (2002). PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90, 703-710.
32. Marx, N., Sukhova, G., Murphy, C., Libby, P., and Plutzky, J. (1998). Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153, 17-23.
33. Masubuchi, Y. (2006). Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet. 21, 347-356.
34. McGuire, D. K., and Inzucchi, S. E. (2008). New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation 117, 440-449.
35. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Sponseller, C. A., Hampton, K., and Bacon, B. R. (2003). Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J. Hepatol. 38, 434-440.
36. Nissen, S. E., and Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471.
37. Oudit, G. Y., Sun, H., Kerfant, B. G., Crackower, M. A., Penninger, J. M., and Backx, P. H. (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 37, 449-471.
38. Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., Fletcher, J. A., Hlatky, L., Hahnfeldt, P., Folkman, J., and Kaipainen, A. (2002). PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110, 923-932.
39. Pasceri, V., Wu, H. D., Willerson, J. T., and Yeh, E. T. (2000). Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101, 235-238.
40. Pomel, V., Klicic, J., Covini, D., Church, D. D., Shaw, J. P., Roulin, K., Burgat-Charvillon, F., Valognes, D., Camps, M., Chabert, C., Gillieron, C., Francon, B., Perrin, D., Leroy, D., Gretener, D., Nichols, A., Vitte, P. A., Carboni, S., Rommel, C., Schwarz, M. K., and Ruckle, T. (2006). Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 49, 3857-3871.
41. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
42. Rogue, A., Spire, C., Brun, M., Claude, N., and Guillouzo, A. (2010). Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res. 2010, 325183.
43. Schupp, M., Janke, J., Clasen, R., Unger, T., and Kintscher, U. (2004). Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109, 2054-2057.
44. Sears, D. D., Hsiao, A., Ofrecio, J. M., Chapman, J., He, W., and Olefsky, J. M. (2007). Selective modulation of promoter recruitment and transcriptional activity of PPARgamma. Biochem. Biophys. Res. Commun. 364, 515-521.
45. Seimandi, M., Lemaire, G., Pillon, A., Perrin, A., Carlavan, I., Voegel, J. J., Vignon, F., Nicolas, J. C., and Balaguer, P. (2005). Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal. Biochem. 344, 8-15.
46. Siarkos, I., Urso, V., Sinagra, T., Drago, F., and Salomone, S. (2011). Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries. Pharmacol. Res. 63, 199-206.
47. Sigrist, S., Bedoucha, M., and Boelsterli, U. A. (2000). Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem. Pharmacol. 60, 67-75.
48. Smith, M. T. (2003). Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16, 679-687.
49. Tao, L., Wang, Y., Gao, E., Zhang, H., Yuan, Y., Lau, W. B., Chan, L., Koch, W. J., and Ma, X. L. (2010). Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ. Res. 106, 409-417.
50. Tenenbaum, A., Motro, M., and Fisman, E. Z. (2005). Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. 4, 14.
51. Vansant, G., Pezzoli, P., Saiz, R., Birch, A., Duffy, C., Ferre, F., and Monforte, J. (2006). Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening. Int. J. Toxicol. 25, 85-94.
52. Wei, S., Yang, J., Lee, S. L., Kulp, S. K., and Chen, C. S. (2009). PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 276, 119-124.
53. Xia, Z., Knaak, C., Ma, J., Beharry, Z. M., McInnes, C., Wang, W., Kraft, A. S., and Smith, C. D. (2009). Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 52, 74-86.
54. Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K., Miki, H., Tsuchida, A., Akanuma, Y., Nagai, R., Kimura, S., and Kadowaki, T. (2001). The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276, 41245-41254.
55. Yang, J., Wei, S., Wang, D. S., Wang, Y. C., Kulp, S. K., and Chen, C. S. (2008). Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents. J. Med. Chem. 51, 2100-2107.